GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

Vaccines Sales Decline: 15% for the quarter due to lower sales of Arexvy and Shingrix ... Phase III readouts and plans for five major new product approvals next year. GSK PLC (NYSE:GSK ...

Vaccines Sales Decline: 15% for the quarter due to lower sales of Arexvy and Shingrix ... with 11 positive Phase III readouts and plans for five major new product approvals next year. GSK PLC ...

Sales of the immuno-inflammation drug Benlysta were up 16% in the quarter, reflecting strong product demand across ... to lower sales of its RSV vaccine Arexvy that fell 72% during the quarter.

that will obviously support the product in that second-line setting. Hi. Thanks for taking my questions. Firstly, I just like to push a little bit on the confidence in the Arexvy revaccination ...

“We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01E-adjuvanted Arexvy, indicating our potential best-in-class ...

GSK's vaccine sales, including RSV and Shingrix, decline amid changing US recommendations, impacting Q3 performance and ...

The U.K. firm, whose vaccines include Arexvy and Shingrix ... to offset lower vaccine sales and reflected successful new product launches in oncology and HIV, as well as the resilience we have ...

The content of this article is provided for information purposes only and is ... So the pipeline is strengthening. The Arexvy development is disappointing for GSK shareholders, as it seemed ...

However, sales across critical divisions were lackluster, with key products such as the respiratory syncytial virus (RSV) vaccine, Arexvy, missing expectations by 21%, and Shingrix sales falling ...

However, sales across critical divisions were lackluster, with key products such as the respiratory syncytial virus (RSV) vaccine, Arexvy, missing expectations by 21%, and Shingrix sales falling short ...